Skip to content

Aims & Scope

The aim of Canadian Hematology Today is to provide clinicians with perspective and insight on the management of hematological disease and to provide a forum for clinicians to share their real-world experience in the treatment and management of their patients.

Journal Editorial Board

Peter Anglin, MD, FRCPC, MBA

Peter Anglin

Dr. Anglin’s clinical focus remains in haematologic and lymphoid malignancies. He is currently Physician Lead for the Stronach Regional Cancer Centre in Newmarket, Ontario. He has also developed an interest in health systems delivery, process redesign in the ambulatory setting, and optimizing drug access for oncology patients. He continues to serve in an advisory capacity to a number of pharmaceutical and health-related organizations. He remains the medical director of CarePath, a cancer navigation and support service supporting Cancer Care Ontario and Ontario cancer patients

Laurie H. Sehn, MD, MPH

Laurie H. Sehn

Dr. Laurie Sehn is currently Clinical Professor with the B.C. Cancer Centre for Lymphoid Cancer and University of British Columbia, Vancouver, Canada. She has been a medical oncologist and clinical investigator at B.C. Cancer since 1998, and is currently the Chair of the Lymphoma Tumour Group. Dr. Sehn graduated from McGill Medical School, Montreal, Canada and received her training in Internal Medicine at Columbia Presbyterian Medical Center, Columbia University, New York, USA. She was trained in Haematology-Oncology at Brigham and Women’s Hospital and the Dana-Farber Cancer Institute, Harvard University, Boston, and received a Masters of Public Health degree from Harvard School of Public Health, Harvard University. Prior to returning to Canada, she spent a year as faculty at the Dana-Farber Cancer Institute with the Bone Marrow Transplantation service. Dr. Sehn’s research interests include population-based outcomes analyses, identification of prognostic factors and predictive biomarkers, and development of novel therapies in lymphoma. Dr. Sehn is Chair of the medical advisory board for the International Lymphoma Coalition. She has also served as a member of the editorial board of Journal of Clinical Oncology and Leukemia Lymphoma, and is currently an Associate Editor for Blood. Dr. Sehn also serves as co-chair of the Lymphoma Site of the Canadian Cancer Trials Group and co-chair of the Lunenburg Lymphoma Biomarker Consortium.

Julie Stakiw, MD, FRCPC

Julie Stakiw

Originally from Saskatchewan, Dr. Stakiw completed her Bachelor of Science, MD and internal medicine training at the University of Saskatchewan prior to moving to Ontario to complete hematology training at Queen’s university followed by a 1 year fellowship at PMH in Lymphoma and Stem Cell Transplant. After working as a hematologist-oncologist at Peel Regional Cancer Center in Mississauga, Ontario for 3 years, she moved back to Saskatchewan in 2010 to be closer to family. Dr. Stakiw has held several leadership positions including Provincial Leader of Hematology for Saskatchewan, the Medical Director of the Saskatchewan Blood and Marrow Transplant Program and most recently Medical Director of Oncology at the Saskatoon Cancer Clinic.

Darrell White, MD, MSc, FRCPC, FACP

Darrell White

Darrell White is a Professor of Medicine and Senior Associate Dean, Faculty of Medicine, Dalhousie University and a hematologist at the Queen Elizabeth II Health Sciences Centre in Halifax, Nova Scotia. Dr. White is a graduate of Dalhousie Medical School, trained in Internal Medicine at the University of Western Ontario and in Hematology at Dalhousie. He completed a fellowship at the Myeloma and Transplantation Research Center at the University of Arkansas. He has completed graduate studies in Community Health and Epidemiology at Dalhousie. Since 1998 he has been a member of the Division of Hematology, Department of Medicine at the Queen Elizabeth II Health Sciences Center in Halifax. His research interest and clinical practice focus on management of multiple myeloma. He is a past chair of the Royal College Specialty Committee in Hematology and past Royal College examiner in internal medicine and hematology. He is a current examiner for hematology with the Canadian Royal College International and the current Board Chair for the Canadian Myeloma Research Group.

Editorial Policy

Canadian Hematology Today has no restrictions on the length of manuscripts, but suggests that the text not be more than 2,000 words exclusive of references, tables, charts and graphs.

The main article types we accept are as follows:

Case Reports (≤1000 words): Case reports should outline a clinical situation that illustrates unique or atypical features or provide a lesson to be learned that is relevant to hematological care. Case reports should include a brief introduction, a description of the case and discussion, including relevance, implications and recommendations. Case reports do not require an abstract. Articles in this section should not exceed 1000 words in length and may contain up to 2 figures and/or tables. The reference list should not exceed 20 references. Written informed consent from the patient(s) or their guardians(s) should be obtained before submission.

Practical Hematology (≤2000 words): Articles under this section should be structured like review articles, be well-referenced and focus on any aspect of the care of people with hematological disease. Practical Hematology articles must also include an abstract, although it need not be structured (maximum 250 words). Practical hematology articles could include review of new resources relevant to the care and education of people with hematological disease. Articles in this section should not exceed 2000 words in length and may contain up to 2 figures and/or tables. The reference list should not exceed 25.

Perspectives in Practice (≤2000 words): This section provides a format for authors to discuss new programs or services, ideas, insights or practical approaches to hematological care and education or professional development. Papers in this section should be well-referenced. Articles in this section should not exceed 2000 words in length and may contain up to 2 figures and/or tables. The reference list should not exceed 25 references.

Innovations in Hematological Care (≤700 words): Papers in this section review new resources relevant to the care and education of people with hematological disease. They may comment on range and depth of contents, readability level, design, approach, price and graphic elements. Articles in this section should not exceed 700 words in length and may contain 1 figure or table. The reference list should not exceed 10 references.

Hematological Dilemmas (≤850 words): This feature is intended to highlight interesting and challenging cases in hematology. This may include: diagnostic considerations, a picture to illustrate a clinical feature, management challenges and complications. The case should illustrate an approach to the problem and provide a succinct summary of take-home points. The case presentation should be 250 words (maximum) and clearly demonstrate the clinical hematological challenge. Alternatively, a picture or illustration can be submitted instead of the case presentation provided it demonstrates the challenge. The case presentation should be followed by a discussion that is 600 words (maximum) outlining the approach to the clinical hematological challenge. One figure or table may be included. Reference list should not exceed 10 references. Written informed consent from the patient(s) or their guardians(s) should be obtained before submission.

Submission Process
Manuscripts for Canadian Hematology Today should be submitted digitally to The submitting author, who is generally the corresponding author, is responsible for the manuscript during the submission and peer-review process and must ensure that queries, revisions and approvals can be provided in a 72-hour time period during the review of their manuscript. Canadian Hematology Today does not charge article processing fees or any other fees for manuscript submission or publication.

Accepted File Formats
Authors must use Microsoft Word to prepare their manuscript. Manuscripts prepared in Microsoft Word must be converted into a single file before submission. When preparing manuscripts in Microsoft Word, please insert graphics (schemes, figures, etc.) in the main text after the paragraph of its first citation.

We do not have strict formatting requirements, but all manuscripts must contain the required sections as appropriate for the type of manuscript being submitted, such as the following in the case of an article:

Author Information, Abstract, Keywords, Introduction, Materials & Methods, Results, Conclusions, Figures and Tables with Captions, Funding Information, Author Contributions, Conflict of Interest and other Ethics Statements.

References are preferred in MLA format but may be submitted in any style, provided that you use the consistent formatting throughout. It is essential to include author(s) name(s), journal or book title, article or chapter title (where required), year of publication, volume and issue (where appropriate) and pagination. DOI numbers (Digital Object Identifier) are not mandatory but highly encouraged. The bibliography software package EndNote, Zotero, Mendeley, Reference Manager are recommended.

Author Biography and Headshot

  • Authors are required to provide a biography (maximum 150 words) with their submission and publish it. This should be a single paragraph and should contain the following points:
  • Authors’ full names followed by current positions;
  • Education background including institution information and year of graduation (type and level of degree received);
  • Work experience;
  • Current and previous research interests;
  • Memberships of professional societies and awards received
  • A hi-resolution headshot must accompany the author’s manuscript. Typically, these can be taken with any current smartphone and should include an image of the author’s full face from the shoulders up.

Peer Review Policy

Canadian Hematology Today is a fully peer-reviewed journal. All articles published in Canadian Hematology Today are subject to review by the Editorial Board, which is comprised of established clinicians with extensive publication records in the field of hematology.

The Editorial Board will evaluate submitted manuscripts against Canadian Hematology Today’s aims and the publication criteria outlined above.

Editors shall disclose any relationships or activities that may bias their review of the manuscript and shall recuse themselves from reviews or editorial decisions that pose a potential conflict of interest.

Advertising Policy

All advertisements and commercially sponsored publications are independent from editorial decisions. Canadian Hematology Today does not endorse any product or service marked as an advertisement or promoted by a sponsor in Canadian Hematology Today publications. Editorial content is not compromised by commercial or financial interests, or by any specific arrangements with advertising clients or sponsors.

All advertisements for drug-specific campaigns must comply with the relevant Canadian legislation that regulates advertising. All advertisements for drug specific campaigns should encourage correct and rational, may not be deceptive or misleading, and must be verifiable. Advertisements should clearly identify the advertiser and the product or service being offered.

Research Ethics & Informed Consent

Canadian Hematology Today reserves the right to reject any manuscript on the basis of unethical conduct in either human or animal studies.

For research involving human experiments, the article must include a statement that ethical approval was obtained (or a statement that ethical approval was not required and why) and a statement that the participants gave informed consent before taking part (or a statement that consent was not required and why).

Identifying details of the participants that were studied should not be published in written descriptions unless the information is essential for scholarly purposes and the participant gave written informed consent for publication.

Where illustrations include recognizable individuals, living or deceased, authors must ensure that consent for publication has been given and patient anonymity should be preserved.

In cases where complete anonymity is difficult to achieve, informed consent for publication must be obtained if there is any doubt.

Corrections & Retractions

Canadian Hematology Today will issue corrections, retraction statements and other post-publication updates including Editorial Expressions of Concern on published content as appropriate. Substantial errors to supplementary information are corrected in the same manner as amendments to the main article.

When making corrections to articles, in the majority of cases the original article is corrected and is linked to and from the published amendment notice, which details the original error. For the sake of transparency, when changes made to the original article affect data in figures, tables or text (for example, when data points/error bars change or curves require redrawing) the amendment notice will reproduce the original data. When it is not possible to correct the original article in both HTML and PDF versions (for example, articles published many years before the error is raised) the article will remain unchanged but will links to and from the published amendment notice.